Aequus Pharmaceuticals Inc (CVE:AQS) reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as C$0.13 and last traded at C$0.14, with a volume of 59500 shares. The stock had previously closed at C$0.13.
The company has a debt-to-equity ratio of 1,096.63, a current ratio of 2.77 and a quick ratio of 2.66. The stock has a market cap of $13.67 million and a price-to-earnings ratio of -4.12. The stock’s 50-day moving average is C$0.15 and its 200 day moving average is C$0.15.
About Aequus Pharmaceuticals (CVE:AQS)
Aequus Pharmaceuticals Inc, a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Zepto, a precision pulse capsulotomy system that provides anterior lens capsulotomies during cataract surgeries; and Topiramate and Oxcarbazepine extended-release tablets for the treatment of epilepsy.
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.